IMC outcomes stratified by the number of SIT doses

Covariate1–2 doses N = 54≥ 3 doses N = 30P
Multiple hospitalization, No. (%)25 (46)10 (33)0.356
Failed steroid tapering after SIT, No. (%)a13 (27)15 (52)0.030
Infliximab, No. (%)49 (91)3 (10)< 0.001
Endoscopic features, No. (%)0.388
Ulcer17 (49)13 (45)
Non-ulcerative inflammation14 (40)9 (31)
Normal4 (11)7 (24)
Endoscopic remission, No. (%)b9 (64)14 (67)1.000
Histologic remission, No. (%)b7 (44)17 (71)0.087
Infectious adverse events, No. (%)16 (30)9 (30)1.000
Recurrent IMC, No. (%)15 (28)1 (3)0.008
Calprotectin after SIT, mean (SD)312 (325)118 (138)0.011
Mean calprotectin difference before and after SIT, (SD)234 (204)222 (165)0.882

aAvailable for the 79 patients who received steroids

bAvailable for 40 patients

Abbreviation: SIT, selective immunosuppressive therapy